Stockscreener 앱 받기
0.209
3.47%
0.007
시장 영업 전:
.22
0.011
+5.26%
전일 마감가:
$0.202
열려 있는:
$0.2012
하루 거래량:
243.85K
Relative Volume:
0.70
시가총액:
$13.49M
수익:
$1.16M
순이익/손실:
$-39.74M
주가수익비율:
-0.3371
EPS:
-0.62
순현금흐름:
$-35.02M
1주 성능:
-8.65%
1개월 성능:
-20.11%
6개월 성능:
-32.56%
1년 성능:
-23.64%
1일 변동 폭
$0.2003
$0.213
1주일 범위
$0.1955
$0.2326
52주 변동 폭
$0.1406
$0.63
Glycomimetics Inc Stock (GLYC) Company Profile
명칭
Glycomimetics Inc
전화
240-243-1201
주소
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
GLYC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLYC
Glycomimetics Inc
|
0.209 | 14.76M | 1.16M | -39.74M | -35.02M | -0.62 |
|
ONC
Beone Medicines Ltd Adr
|
251.72 | 25.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.48 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3401 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.81 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.86 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-26 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-22 | 개시 | CapitalOne | Overweight |
| 2021-11-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-05 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2018-12-18 | 개시 | H.C. Wainwright | Buy |
| 2016-07-26 | 개시 | SunTrust | Buy |
| 2015-03-17 | 재확인 | Stifel | Buy |
모두보기
Glycomimetics Inc 주식(GLYC)의 최신 뉴스
GlycoMimetics Announces Merger Amidst Uncertainties - TipRanks
GlycoMimetics executives to depart amid merger plans - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, LRFC, RDW, GLYC on Behalf of Shareholders - TradingView
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NDOI, SSBK, BRDG on Behalf of Shareholders - GlobeNewswire Inc.
GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com - Defense World
GlycoMimetics (NASDAQ:GLYC) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World
GlycoMimetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc.GLYC - marketscreener.com
GlycoMimetics: Q1 Earnings Snapshot - CT Insider
GLYCOMIMETICS INC SEC 10-Q Report - TradingView
StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics, Inc. to Host Earnings Call - ACCESS Newswire
$TOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The MergerGLYC, BRZH, PRA, FVNNU - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COLB, PRA, GLYC on Behalf of Shareholders - Finansavisen
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – GLYC, BRZH, PRA, FVNNU - TradingView
A Stock Analysis Of GlycoMimetics Inc’s (GLYC) - Stocksregister
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com - Defense World
Ratios Revealed: Decoding GlycoMimetics Inc (GLYC)’s Financial Health - DWinneX
GlycoMimetics Inc (GLYC Stock: A Sea of Opportunity - investchronicle.com
Cantor Fitzgerald initates GlycoMimetics Inc (GLYC) rating to an Overweight - knoxdaily.com
GlycoMimetics Amends Merger Agreement With Crescent Biopharma - Investing.com
GlycoMimetics, Inc. (GLYC) Stock Report: Analyst Ratings Signal Potential in Biotech Space - DirectorsTalk Interviews
Press Release Distribution & PR Platform - ACCESS Newswire
A Look at GlycoMimetics Inc (GLYC) Shares in the Recent Past Indicates Growth - Sete News
GLYC Shares Experience Surge in Value - knoxdaily.com
GlycoMimetics (NASDAQ:GLYC) Stock Price Passes Below 200 Day Moving Average – Time to Sell? - Defense World
GlycoMimetics Inc (GLYC) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Understanding GLYC stock ratios for better investment decisions - uspostnews.com
GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World
Wellington Management Group LLP Makes New Investment in GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World
GlycoMimetics, Inc. Announces Efficacy and Safety Data from Phase 1/2 Clinical Study of Uproleselan Published in BLOOD - MarketScreener
Crescent moon shot to scale the Summit in VEGFxPD-1 - BioWorld MedTech
Form 425 GLYCOMIMETICS INC Filed by: GLYCOMIMETICS INC - StreetInsider
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics - Quantisnow
GLYCOMIMETICS Earnings Preview: Recent $GLYC Insider Trading, Hedge Fund Activity, and More - Nasdaq
Cantor Fitzgerald Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
Cantor Fitzgerald maintains Overweight on GlycoMimetics stock By Investing.com - Investing.com Australia
Cantor Fitzgerald Initiates Coverage of GlycoMimetics (GLYC) with Overweight Recommendation - MSN
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated by Analysts at StockNews.com - Defense World
Glycomimetics Inc (GLYC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.19%
자본화:
|
볼륨(24시간):